BIOAGE LABS INC (BIOA)
US09072Q1067
BIOAGE LABS INC
NASDAQ:BIOA (10/11/2024, 8:00:02 PM)
After market: 21.7 0 (0%)21.7
+1.16 (+5.65%)
Company Profile
BIOAGE Labs Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Richmond California, California and currently employs 58 full-time employees. The company went IPO on 2024-09-26. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product candidate, azelaprag, is an orally available small molecule agonist of the apelin receptor (APJ) that was observed to promote metabolism and prevent muscle atrophy during bed rest in a Phase Ib clinical trial. The company has initiated a Phase II trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has the potential as an oral regimen to reduce weight loss and improve body composition in patients on obesity therapy with incretin drugs. The company is also developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. Its preclinical programs, based on novel insights from the Company’s discovery platform built on human longevity data, address key pathways in metabolic aging.
Company Info
BIOAGE LABS INC
1445A South 50Th Street
Richmond California CALIFORNIA H3B 4W8
P: 15108061445
CEO: Fabrice Orecchioni
Employees: 58
Website: https://bioagelabs.com
BIOA News
16 hours ago - The Motley FoolInterested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO StockBioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm.
6 days ago - The Motley Fool2 Next-Gen Weight Loss Stocks That Are Worth Buying Right NowOne of these businesses is a risky play, but the other is very likely to succeed.
8 days ago - The Motley Fool3 Reasons to Buy BioAge Labs Stock Hand Over Fist in OctoberThere's a chance that its lead candidate could become one of the top drugs ever.
10 days ago - The Motley FoolThis IPO Biotech Stock Could Be the Next Eli LillyBioAge has its eyes on a handful of truly gargantuan markets.
12 days ago - BioAge Labs, Inc.BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement12 days ago - BioAge Labs, Inc.BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private PlacementRICHMOND, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing...
BIOA Twits
Here you can normally see the latest stock twits on BIOA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
